Endocarditis due to gram-negative bacilli at a French teaching hospital over a 6-year period: clinical characteristics and outcome

Infect Dis (Lond). 2015;47(12):889-95. doi: 10.3109/23744235.2015.1075660. Epub 2015 Aug 11.

Abstract

Background: Infective endocarditis (IE) due to gram-negative bacilli (GNB) is rare. However, several studies described a change in the epidemiological profile of patients within the past few years.

Methods: We reviewed all cases diagnosed and followed in the infectious diseases ward of a French teaching hospital in Paris between 2009 and 2014, inclusive.

Results: Among the 17 patients with definite GNB-IE (11 male, mean age 54 years), 12 (70%) were due to non-HACEK GNB and 5 (30%) to HACEK group GNB. A prosthetic valve was involved in 10 cases (8 in non-HACEK and 2 in HACEK group). Escherichia coli (4/12 patients) and Pseudomonas aeruginosa (3/12 patients) were the most common pathogens in the first group; all the pathogens in the second group were Haemophilus spp. One-third of the patients with non-HACEK GNB had nosocomial IE, whereas injection drug use-related infections were rare (2/12). All patients with HACEK infection had at least one complication (intracardiac abscess, stroke or other systemic embolization). All patients were treated by antibiotic combination therapy during a median time of 42 days (interquartile range (IQR) = 42-42) and 10 (59%) underwent cardiac surgery. One death at 9 months was observed in the non-HACEK group.

Conclusions: Regarding HACEK IE, this report supports the frequent association with vascular complications. Regarding non-HACEK GNB IE, this report supports the increasing proportion of nosocomial infections. We reported a high proportion of surgery in the therapeutic management of both HACEK and non-HACEK groups associated with no in-hospital mortality.

Keywords: Endocarditis; Enterobacteriaceae; HACEK; gram-negative bacilli; non-HACEK.

MeSH terms

  • Abscess / microbiology
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Cardiac Surgical Procedures / adverse effects
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology*
  • Cross Infection / microbiology
  • Drug Therapy, Combination
  • Endocarditis, Bacterial / drug therapy
  • Endocarditis, Bacterial / epidemiology*
  • Endocarditis, Bacterial / microbiology*
  • Escherichia coli / isolation & purification
  • Female
  • Gram-Negative Bacteria / classification
  • Gram-Negative Bacteria / isolation & purification*
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / epidemiology*
  • Gram-Negative Bacterial Infections / microbiology
  • Haemophilus / isolation & purification
  • Hospital Mortality
  • Hospitals, Teaching*
  • Humans
  • Male
  • Middle Aged
  • Paris / epidemiology
  • Pseudomonas aeruginosa / isolation & purification
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents